Melanostatin DM
Also known as: Melanostatin DM, Nonapeptide-1
Melanostatin DM is a topical nonapeptide marketed as a skin-brightening agent that reduces melanin production. It is studied for evening skin tone and lightening hyperpigmentation.
Last updated
Mechanism of Action
Melanostatin DM is built around Nonapeptide-1, a sequence designed to antagonize the melanocortin-1 receptor (MC1R) on melanocytes. By competing with alpha-MSH at MC1R it suppresses downstream cAMP signaling and microphthalmia-associated transcription factor (MITF) activation, reducing transcription of tyrosinase and related melanogenic enzymes. The net effect is decreased melanin synthesis and a more even, lighter skin tone with continued topical use.
- Half-life
- Local topical action over hours; not systemically relevant
- Administration Routes
- topical
- Research Status
- Research Chemical
Reported Benefits
- Reduces melanin synthesis for skin brightening
- Helps even out hyperpigmentation and dark spots
- Acts upstream at MC1R rather than only inhibiting tyrosinase
- Suitable for topical cosmetic formulation
- May complement other depigmenting agents
Potential Side Effects
- Mild localized irritation or dryness
- Possible contact sensitivity to formulation
- Gradual and modest effect requiring sustained use
Common Dosing
For research use only, not medical advice. Cosmetic formulations typically reference low single-digit percentage concentrations applied topically once or twice daily; this is not a personal-use recommendation.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Known hypersensitivity to the peptide
- Application to broken or irritated skin
- View
Enhanced skin benefits of EGCG loaded in nonapeptide-1-conjugated mesoporous silica nanoparticles to reverse skin photoaging
2024